Former Foundation René Touraine’s president Louis Dubertret explain what we should not think about psoriasis so as to better deal with it.
Former Foundation René Touraine’s president Louis Dubertret explain what we should not think about psoriasis so as to better deal with it.
Is psoriasis contagious ?
No. For instance, you can go without any risk to the swimming pool when your suffer from psoriasis. On the contrary, skins affected by psoriasis contain much more anti-infectious molecules than a normal skin. The risk is consequently lower.
Is psoriasis hereditary ?
This is a frequent question as psoriasis is a genetical disease. However, the transmission does not occur in a mathematical way involving one specific gene, but because of predisposition factors. A similar situation arises when a mother suffers from hay fever. Her children are likely to develop this disease, but nothing is statistically predictable. This concern about the children often grows in a case of severe psoriasis. It has to be reminded that when you mix your genes with those of another parent who is not affected by the disease, your children can only have, at worst, a more moderate form of psoriasis. Also, treatments are becoming increasingly efficient, which is a opportunity for us to stop perceiving psoriasis as a curse passed on from generation to generation.
If the cure is not working well, do I have to see another doctor ?
As the symptoms of psoriasis differ for each individual, the patients benefits from a priceless insight giving them information a doctor cannot know. Any patient willing to improve their condition have to communicate consistently about the evolution of their disease in order to enable their doctor to adjust the treatment progressively. Hence, it is a mistake to change your physician since it will make you start from scratch. Thus, it seems better to be patient enough to explain regularly to your doctor why you still are dissatisfied with your current treatment, so that he or she eventually finds the ideal one. This is all the more significant as no pratictioner can have an exhaustive knowledge, especially in the case of a disease that flares up differently for each patient.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Uncovering the mechanism of Jueyin granules in the treatment of psoriasis using network pharmacology.
J Ethnopharmacol.
2020 Nov 15, 262:113214.
Our clinical practice demonstrated that Jueyin granules (JYG) benefit patients with mild to moderate psoriasis vulgaris without apparent adverse effects. JYG have been shown to inhibit epidermal proliferation in an imiquimod (IMQ)-induced psoriasis-like mouse model, as well as keratinocyte proliferation. Moreover, JYG causes no acute or chronic toxicity in animal models. However, its related molecular mechanism has still not been (...)
see on pubmed
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.
Drug Deliv.
2020 Dec , 27, (1):662-680.
Psoriasis is a dermatological chronic skin condition with underlying autoimmune etiology. It deeply affects patients' quality of life. Therefore, it was an interesting target for researchers throughout the past years. Conventionally, the treatment options include anti-inflammatory agents, immune suppressants, biologic treatment, and phototherapy. Nanotechnology offers promising characteristics that allow for tailoring a drug carrier to achieve dermal targeting, improved efficacy and (...)
see on pubmed
In silico data mining of large-scale databases for the virtual screening of human interleukin-2 inhibitors.
Acta Pharm.
2021 Mar 01, 71, (1):33-56.
Interleukin-2 (IL-2) is involved in the activation and differentiation of T-helper cells. Uncontrolled activated T cells play a key role in the pathophysiology by stimulating inflammation and autoimmune diseases like arthritis, psoriasis and Crohn's disease. T cells activation can be suppressed either by preventing IL-2 production or blocking the IL-2 interaction with its receptor. Hence, IL-2 is now emerging as a target for novel therapeutic approaches in several autoimmune disorders. This (...)
see on pubmed
on Atopic Dermatitis
Enhanced Type 2 Immune Reactions by Increased IL-22/IL-22Ra1 Signaling in Chronic Rhinosinusitis With Nasal Polyps.
Allergy Asthma Immunol Res.
2020 Nov , 12, (6):980-993.
Recent studies have revealed the pathogenic role of interleukin (IL)-22 in atopic dermatitis and asthma. However, little is known about the role of IL-22 in the pathophysiology of chronic rhinosinusitis with nasal polyps. We aimed to investigate the expression of IL-22 and its pathogenic function in type 2 immune reactions of nasal polyps (NP).
see on pubmed
Facial Redness in Atopic Dermatitis Patients Treated With Dupilumab: A Case Series.
Seok SH et al.
Facial Redness in Atopic Dermatitis Patients Treated With Dupilumab: A Case Series.
Allergy Asthma Immunol Res.
2020 Nov , 12, (6):1063-1065.
Update on canine filaggrin: a review.
Combarros D et al.
Update on canine filaggrin: a review.
Vet Q.
2020 Dec , 40, (1):162-168.
Human filaggrin (FLG) plays a key role in epidermal barrier function, and loss-of-function mutations of its gene are primarily responsible for the development of human atopic dermatitis (AD). FLG expression is also reduced in the epidermis of atopic patients, due to the transcriptional effect of Th2 type cytokines. Canine atopic dermatitis (CAD) is a prevalent skin disease that shares many clinical and pathogenic features with its human homologue. The aim of this review is discuss current (...)
see on pubmed
